Information on EC 3.4.24.86 - ADAM 17 endopeptidase

New: Word Map on EC 3.4.24.86
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eutheria

EC NUMBER
COMMENTARY hide
3.4.24.86
-
RECOMMENDED NAME
GeneOntology No.
ADAM 17 endopeptidase
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
Narrow endopeptidase specificity. Cleaves Pro-Leu-Ala-Gln-Ala-/-Val-Arg-Ser-Ser-Ser in the membrane-bound, 26-kDa form of tumor necrosis factor alpha (TNFalpha). Similarly cleaves other membrane-anchored, cell-surface proteins to 'shed' the extracellular domains
show the reaction diagram
proTNF-alpha + H2O = soluble TNF-alpha. Cleavage of the precursor of tumor necrosis factor proTNFalpha to the mature tumor necrosis factor TNF-alpha, Swiss-Prot Acesssion Numbers: P78536(human), Q77636(pig), Q9Z1K9(rat), Q9Z0F8(mouse), Q923X3(chinese hamster). In peptidase family M12. In vivo, the cleavage of tumor necrosis factor alpha precursor releases the soluble, 17-kDa TNFa, which induces inflammation.
-
-
-
CAS REGISTRY NUMBER
COMMENTARY hide
151769-16-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
african green monkey, COS-7, an SV40 transformed kidney cell line
-
-
Manually annotated by BRENDA team
Mus musculus AC2/G3
strain AC2/G3
-
-
Manually annotated by BRENDA team
Mus musculus C3H/HEN
strain C3H/HEN
-
-
Manually annotated by BRENDA team
wild-type EC-4
-
-
Manually annotated by BRENDA team
rabbit
-
-
Manually annotated by BRENDA team
strain Lewis
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(7-methoxycoumarin-4-yl)-acetyl-KSPLAQA-VRSSSRK(2,4-dinitrophenyl)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-Pro-Leu-Ala-Gln-Ala-Val-[N-3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl]-Arg-Ser-Ser-Ser-Arg-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-SPLAQAVRSSSRK-(2,4-dinitrophenyl)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-Ser-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys(Dnp)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(EDANS)-ELAQAVRSSSRK-(DABCYL) + H2O
?
show the reaction diagram
-
TNF-alpha derived substrate
-
-
?
(EDANS)-EPLAQAVRSSSK-(DABCYL) + H2O
?
show the reaction diagram
-
TNF-alpha derived substrate
-
-
?
26 kDa proTNF-alpha + H2O
17 kDa soluble TNF-alpha + ?
show the reaction diagram
-
-
-
-
?
4',5'-dimethoxyfluoresceinyl-SPLAQAVRSSSR-cys(4-(3-succinimid-1-yl)fluorescein)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
7-methoxycoumarin-4-(yl)acetyl-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Arg-NH2 + H2O
?
show the reaction diagram
-
an internally quenched peptide substrate is used
-
-
?
7-methoxycoumarin-4-yl-acetyl-Lys-Pro-Leu-Gly-Pro-Leu-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
75kDaTNFR2 + H2O
?
show the reaction diagram
ACE2 + H2O
?
show the reaction diagram
-
-
-
-
?
acetyl-SPLAQAVRSSSR-COOH + H2O
acetyl-SPLAQA + VRSSSR-COOH
show the reaction diagram
-
-
-
-
?
ALCAM + H2O
?
show the reaction diagram
-
-
-
-
?
Alzheimer's disease amyloid precursor protein + H2O
?
show the reaction diagram
amphiregulin + H2O
?
show the reaction diagram
amyloid-protein precursor + H2O
?
show the reaction diagram
-
-
-
-
?
angiotensin-converting enzyme-2 + H2O
?
show the reaction diagram
AREG + H2O
?
show the reaction diagram
-
-
-
-
?
beta-amyloid precursor protein + H2O
?
show the reaction diagram
BTC + H2O
?
show the reaction diagram
-
-
-
-
?
c-KLR + H2O
?
show the reaction diagram
-
-
-
-
?
CD16 + H2O
? |
show the reaction diagram
-
substrates CD16a and CD16b are IgG Fc receptors expressed by human natural killer cells and neutrophils, respectively. Substrates contain three separate cleavage sites in close proximity at P1/P1' positions Ala195/Val196, Val196/Ser197, and Thr198/Ile199, revealing a membrane proximal cleavage region in CD16. Mutation S197P effectively blocks CD16a and CD16b cleavage in cell-based assays. Mutant CD16a/S197P is resistant to cleavage when expressed in cells. The S197P mutation does not disrupt IgG binding by the receptor or its activation of NK92 cells by antibody-treated tumor cells
-
-
?
CD163 + H2O
?
show the reaction diagram
-
-
-
-
?
CD16b + H2O
?
show the reaction diagram
-
human IgG Fc receptor CD16, i.e. FcgammaRIII. CD16b plasma levels are significantly decreased in patients administered a selective inhibitor targeting the metalloproteases ADAM10 and ADAM17. Inhibition of ADAM17 significantly blocks the cleavage of CD16b following neutrophil activation and apoptosis
-
-
?
CD26L + H2O
?
show the reaction diagram
-
-
-
-
?
CD30 + H2O
?
show the reaction diagram
CD40 + H2O
?
show the reaction diagram
-
-
-
-
?
CD44 + H2O
?
show the reaction diagram
-
-
-
-
?
CD89 + H2O
?
show the reaction diagram
-
-
-
-
?
CD91 + H2O
?
show the reaction diagram
-
-
-
-
?
cell surface VEGF receptor Flt + H2O
?
show the reaction diagram
-
-
release of an N-terminal extracellular fragment which can antagonize the effects of vascular endothelial growth factor, substrate can be cleaved to release an N-terminal extracellular fragment. Overexpression of ADAM10, EC 3.4.24.81, and ADAM17 increase cleavage while knockdown of ADAM10 and ADAM17 reduce N-terminal cleavage
-
?
cellular prion protein PrPc + H2O
?
show the reaction diagram
-
-
-
-
?
collagen type XVII + H2O
?
show the reaction diagram
-
-
-
-
?
CSF-1 + H2O
?
show the reaction diagram
-
-
-
-
?
CSF-1 receptor + H2O
?
show the reaction diagram
-
TACE cleaves the receptor between residues Gln503 and Ser504. Replacement of fourteen residues at the end of the CSF-1 extracellular domain blocks TACE cleavage
-
-
?
CSF1R + H2O
?
show the reaction diagram
-
-
-
-
?
DLL1 + H2O
?
show the reaction diagram
-
-
-
-
?
Dpa-SPLAQAVRSSSR-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
DSG2 + H2O
?
show the reaction diagram
-
-
-
-
?
endothelial protein C receptor + H2O
?
show the reaction diagram
-
-
-
-
?
EpCAM + H2O
?
show the reaction diagram
-
-
-
-
?
EPCR + H2O
?
show the reaction diagram
-
-
-
-
?
epidermal growth factor receptor + H2O
?
show the reaction diagram
-
-
-
-
?
epigen + H2O
?
show the reaction diagram
-
-
-
-
?
epiregulin + H2O
?
show the reaction diagram
-
-
-
-
?
EPR + H2O
?
show the reaction diagram
-
-
-
-
?
ErbB4 + H2O
?
show the reaction diagram
-
-
-
-
?
erbB4/HER4 + H2O
?
show the reaction diagram
EREG + H2O
?
show the reaction diagram
-
-
-
-
?
FcalphaR + H2O
?
show the reaction diagram
-
i.e. Fc receptor for immunoglobulin A
-
-
?
FLT-3L + H2O
?
show the reaction diagram
-
-
-
-
?
fractalkine + H2O
?
show the reaction diagram
GHR + H2O
?
show the reaction diagram
-
-
-
-
?
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL) + H2O
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala + Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL)
show the reaction diagram
-
-
-
-
?
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Lys(DABCYL) + H2O
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala + Val-Arg-Ser-Ser-Ser-Lys(DABCYL)
show the reaction diagram
-
-
-
-
?
glycoprotein Ibalpha + H2O
?
show the reaction diagram
glycoprotein V + H2O
?
show the reaction diagram
-
-
-
-
?
GPIba + H2O
?
show the reaction diagram
-
-
-
-
?
growth factor alpha + H2O
?
show the reaction diagram
-
-
-
-
?
growth hormone binding protein + H2O
?
show the reaction diagram
-
shedding, TACE is critical for PMA-induced GH receptor proteolysis and GHBP generation
-
-
?
growth hormone receptor + H2O
?
show the reaction diagram
-
growth hormone receptor/TACE interaction precedes proteolysis and is transient
-
-
?
HB-EGF + H2O
?
show the reaction diagram
-
-
-
-
?
HB-EGF heparin binding epidermal growth factor + H2O
?
show the reaction diagram
-
-
-
-
?
heparin-binding EGF-like growth factor + H2O
?
show the reaction diagram
heparin-binding epidermal growth factor-like growth factor + H2O
?
show the reaction diagram
-
-
-
-
?
HER-4 Jma + H2O
?
show the reaction diagram
-
-
-
-
?
heregulin + H2O
?
show the reaction diagram
-
-
-
-
?
ICAM-1 + H2O
?
show the reaction diagram
-
-
-
-
?
IGF-2 receptor + H2O
?
show the reaction diagram
-
-
-
-
?
intercellular adhesion molecule-1 + H2O
?
show the reaction diagram
intercellular cell adhesion molecule-1 + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin (IL)-1R-II + H2O
?
show the reaction diagram
interleukin (IL)-6R + H2O
?
show the reaction diagram
exclusively the extracellular domains of ADAM17 are needed for interaction with substrate, whereas the transmembrane- and cytoplasmic-region are dispensable for this process. In the extracellular part solely the membrane-proximal domain of ADAM17 is mandatory for recognition
-
-
?
interleukin-1 receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin-6 receptor + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is LPVQ357-/-DSSV, N-linked glycosylation sites are: Asn55, Asn93, Asn221, Asn350
-
-
?
interleukin-6 receptor + H2O
soluble interleukin-6 receptor + ?
show the reaction diagram
-
-
-
-
?
interleukin-6-receptor + H2O
?
show the reaction diagram
-
-
-
-
?
Jagged protein + H2O
?
show the reaction diagram
-
-
-
-
?
JAM-A + H2O
?
show the reaction diagram
-
-
-
-
?
KL-1 + H2O
?
show the reaction diagram
KL-2 + H2O
?
show the reaction diagram
-
-
-
-
?
L-selectin + H2O
?
show the reaction diagram
L1-CAM + H2O
?
show the reaction diagram
-
-
-
-
?
LAG-3 + H2O
?
show the reaction diagram
-
-
-
-
?
LAQAVRSSSR + H2O
?
show the reaction diagram
-
fluorimetric assay for TACE, fluorogenic substrate, a 10-amino-acid peptide capped with an o-aminobenzoyl group on the N-terminal end and with a 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionic amide group on the C-terminal end, enzymatic conversion of the substrate results in a fluorescence enhancement of 11fold
-
-
?
lipoprotein-related protein I + H2O
?
show the reaction diagram
-
lipoprotein-related protein I shedding is significantly decreased in embryonic fibroblast cells lacking ADAM10 and/or ADAM17
-
-
?
LOX-1 + H2O
?
show the reaction diagram
-
-
-
-
?
lymphotoxin-alpha + H2O
?
show the reaction diagram
-
-
-
-
?
LYPD3 + H2O
?
show the reaction diagram
-
-
-
-
?
macrophage colony-stimulating factor receptor M-CSFR + H2O
?
show the reaction diagram
-
-
-
-
?
Mca-PLAQAV-Dpa-RSSSR-NH2 + H2O
Mca-PLAQA + V-Dpa-RSSSR-NH2
show the reaction diagram
-
-
-
-
?
Mca-PLAQAV-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide-RSSSR-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
MHC class I-related chain + H2O
?
show the reaction diagram
-
i.e. transmembrane protein expressed in pathological conditions, ligands for the activating receptor NKG2D found on cytotoxic lymphocytes. The recruitment of both enzyme and substrate to detergent-resistant membrane microdomains is crucial for efficient proteolysis
-
-
?
MICA + H2O
?
show the reaction diagram
-
-
-
-
?
MICB + H2O
?
show the reaction diagram
-
-
-
-
?
MUC-1 + H2O
?
show the reaction diagram
-
-
-
-
?
NCAM + H2O
?
show the reaction diagram
-
-
-
-
?
nectin-4 + H2O
?
show the reaction diagram
-
-
-
-
?
NH2-LAQAVRSSSR-OH + H2O
?
show the reaction diagram
-
uncapped counterpart of the fluorogenic substrate
-
-
?
Notch 1 + H2O
?
show the reaction diagram
-
ADAM17 is required for Notch1 receptor proteolysis in NSCLC cells in vitro and in vivo
-
-
?
notch 1 receptor + H2O
?
show the reaction diagram
-
-
-
-
?
Notch1 + H2O
?
show the reaction diagram
NPR + H2O
?
show the reaction diagram
-
-
-
-
?
o-aminobenzoyl-LAQAFRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + FRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 22%
-
-
?
o-aminobenzoyl-LAQAIRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + IRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 66%
-
-
?
o-aminobenzoyl-LAQALRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + LRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 92%
-
-
?
o-aminobenzoyl-LAQAVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 90%
-
-
?
o-aminobenzoyl-LAQFVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQF + RSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 39%
-
-
?
o-aminobenzoyl-LAQGVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQG + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 11%
-
-
?
o-aminobenzoyl-LAQLVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQL + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 34%
-
-
?
o-aminobenzoyl-LAQVARSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQVA + RSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 19%
-
-
?
p55 TNF-alpha RI + H2O
?
show the reaction diagram
-
-
-
-
?
p55 TNFR1 + H2O
?
show the reaction diagram
p75 neurotrophin receptor + H2O
?
show the reaction diagram
p75 TNF-alpha RII + H2O
?
show the reaction diagram
-
-
-
-
?
p75 tumour necrosis factor receptor + H2O
?
show the reaction diagram
p75NTR + H2O
?
show the reaction diagram
-
-
-
-
?
PLAAAVFSS + H2O
PLAAA + VFSS
show the reaction diagram
-
mutant peptide derived from TNF-alpha, very poor substrate
-
-
?
PLAMAVMSS + H2O
PLAMA + VMSS
show the reaction diagram
-
mutant peptide derived from TNF-alpha, very poor substrate
-
-
?
PLAQAVRSS + H2O
PLAQA + VRSS
show the reaction diagram
-
peptide derived from TNF-alpha
-
-
?
PMEL17 + H2O
?
show the reaction diagram
-
-
-
-
?
pN-collagen I substrate + H2O
?
show the reaction diagram
-
-
-
-
?
preadipocyte factor 1 + H2O
?
show the reaction diagram
Pref1 + H2O
?
show the reaction diagram
-
-
-
-
?
pro amphiregulin + H2O
?
show the reaction diagram
-
TACE is capable of cleaving both N- and C-terminal sites in the pro-amphiregulin ectodomain
-
-
?
pro heparin-binding epidermal growth factor + H2O
?
show the reaction diagram
-
purified soluble TACE cleaves a single site in the juxtamembrane stalk of pro heparin-binding epidermal growth factor
-
-
?
Pro-BTC + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is CVVA31-/-DGNS, N-linked glycosylation site is Asn34
-
-
?
pro-EGF receptor + H2O
EGF receptor + ?
show the reaction diagram
-
-
-
-
?
pro-EPR + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is DNPR59-/-VAQV, N-linked glycosylation site is Asn47
-
-
?
pro-HB-EGF + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is RKVR62-/-DLQE, O-linked glycosylation sites are Thr75 and Thr85
-
-
?
pro-interleukin-6 receptor + H2O
interleukin-6 receptor + ?
show the reaction diagram
-
-
-
-
?
pro-L-selectin + H2O
L-selectin + ?
show the reaction diagram
-
-
-
-
?
pro-Notch 1 + H2O
Notch 1 + ?
show the reaction diagram
-
-
-
-
?
pro-TGF-alpha + H2O
mature growth factor
show the reaction diagram
-
-
-
-
?
pro-TGFalpha + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is VAAA39-/-VVSH, N-linked glycosylation site is Asn25
-
-
?
pro-TNF-alpha + H2O
soluble TNF-alpha + ?
show the reaction diagram
-
-
-
-
?
pro-tumor necrosis factor alpha + H2O
?
show the reaction diagram
-
with and without a glycan moiety attached, glycosylation increases the enzyme activity. The cleavage site of TNFalpha by ADAM17 is only four residues away from a glycosylated residues, whereas glycosylation occurs 14 residues away from the TGFalpha cleavage site. Cleavage site for ADAM-17 is LAQA76-/-VRSS, O-linked glycosylation site is Ser80
-
-
?
proheparin-binding EGF-like growth factor + H2O
?
show the reaction diagram
-
-
cleavage occurs between residues RKVR62-DLQE. Substrate shows O-linked glycosylation 13 residues apart from scissile bond
-
?
protein C receptor + H2O
?
show the reaction diagram
-
-
-
-
?
proTGF-alpha + H2O
soluble TGF-alpha
show the reaction diagram
proTNF-alpha + H2O
soluble TNF-alpha
show the reaction diagram
proTNF-alpha + H2O
soluble TNF-alpha + 9000 Da membrane-bound fragment of TNF-alpha
show the reaction diagram
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha + ?
show the reaction diagram
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha + H2O
show the reaction diagram
-
-
cleavage occurs between residues LAQA76-VRSS. Substrate shows O-linked glycosylation 4 residues apart from scissile bond
-
?
protransforming growth factor alpha + H2O
?
show the reaction diagram
-
-
cleavage occurs between residues AAA39-VVSH. Substrate shows N-linked glycosylation 14 residues apart from scissile bond
-
?
PrPc + H2O
?
show the reaction diagram
-
-
-
-
?
Prprz + H2O
?
show the reaction diagram
-
-
-
-
?
PTP-LAR + H2O
?
show the reaction diagram
-
-
-
-
?
RA175/SynCAM1 + H2O
?
show the reaction diagram
-
neuronal RA175/SynCAM1 isoforms, members of the immunoglobulin family 4, are processed by TACE
-
-
?
RANKL + ?
?
show the reaction diagram
-
-
-
-
?
receptor tyrosine kinase c-Kit + H2O
?
show the reaction diagram
S80-glycosylated (EDANS)-ELAQAVRSSSRK-(DABCYL) + H2O
?
show the reaction diagram
-
TNF-alpha derived substrate
-
-
?
S80-glycosylated (EDANS)-EPLAQAVRSSSK-(DABCYL) + H2O
?
show the reaction diagram
-
TNF-alpha derived substrate
-
-
?
SDC1 + H2O
?
show the reaction diagram
-
-
-
-
?
SDC4 + H2O
?
show the reaction diagram
-
-
-
-
?
SEMA4D + H2O
?
show the reaction diagram
-
-
-
-
?
soluble TNF + H2O
?
show the reaction diagram
-
-
-
-
?
soluble TNF receptor 1 + H2O
?
show the reaction diagram
-
-
-
-
?
soluble TNF receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
soluble TNF-alpha receptor type 1 + H2O
?
show the reaction diagram
-
-
-
-
?
SORCS1 + H2O
?
show the reaction diagram
-
-
-
-
?
sorCS1c + H2O
?
show the reaction diagram
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors
-
-
?
sorCS2 + H2O
?
show the reaction diagram
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors, minor shedding
-
-
?
sorCS3 + H2O
?
show the reaction diagram
SORL1 + H2O
?
show the reaction diagram
-
-
-
-
?
sorLA + H2O
?
show the reaction diagram
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors
-
-
?
SORT1 + H2O
?
show the reaction diagram
-
-
-
-
?
sortilin + H2O
?
show the reaction diagram
-
member of the vacuolar protein sorting 10p domain family of neuronal type-I receptors, minor shedding
-
-
?
syndecan-1 + H2O
?
show the reaction diagram
-
both ADAM10 and ADAM17 contribute to SDC1 shedding
-
-
?
TGF-alpha + H2O
?
show the reaction diagram
-
ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding
-
-
?
TMEF2 + H2O
?
show the reaction diagram
-
-
-
-
?
TNF-alpha + H2O
?
show the reaction diagram
TNF-alpha + H2O
soluble TNF-alpha
show the reaction diagram
TRANCE + H2O
?
show the reaction diagram
-
-
-
-
?
TRANCE/RANKL + H2O
?
show the reaction diagram
-
-
-
-
?
transferrin receptor protein 1 + H2O
?
show the reaction diagram
-
-
cleavage occurs between residues ECER100-LAGT. Substrate shows O-linked glycosylation 4 residues apart from scissile bond
-
?
transforming growth factor alpha + H2O
?
show the reaction diagram
transforming growth factor-alpha + H2O
?
show the reaction diagram
-
-
-
-
?
TrkA + H2O
?
show the reaction diagram
-
-
-
-
?
TRP1 + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is ECER100-/-LAGT, O-linked glycosylation sites are: Thr104, Asn251, Asn317, Asn727
-
-
?
tumor necrosis factor receptor 1 + H2O
?
show the reaction diagram
-
ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding
-
-
?
tumour necrosis factor receptor-1 + H2O
?
show the reaction diagram
-
-
-
-
?
tumour necrosis factor receptor-2 + H2O
?
show the reaction diagram
-
-
-
-
?
vascular cellular adhesion molecule-1 + H2O
?
show the reaction diagram
-
-
-
-
?
vasorin + H2O
?
show the reaction diagram
-
-
-
-
?
vasorin + H2O
soluble vasorin + ?
show the reaction diagram
-
-
-
-
?
VCAM-1 + H2O
?
show the reaction diagram
-
-
-
-
?
VEGFR2 + H2O
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
Alzheimer's disease amyloid precursor protein + H2O
?
show the reaction diagram
-
TACE is involved in shedding of Alzheimer's disease amyloid precursor protein
-
-
?
amphiregulin + H2O
?
show the reaction diagram
-
-
-
-
?
angiotensin-converting enzyme-2 + H2O
?
show the reaction diagram
-
ADAM-17 is responsible for the ACE2 shedding
-
-
?
AREG + H2O
?
show the reaction diagram
-
-
-
-
?
CD26L + H2O
?
show the reaction diagram
-
-
-
-
?
epidermal growth factor receptor + H2O
?
show the reaction diagram
-
-
-
-
?
epiregulin + H2O
?
show the reaction diagram
-
-
-
-
?
FLT-3L + H2O
?
show the reaction diagram
-
-
-
-
?
glycoprotein Ibalpha + H2O
?
show the reaction diagram
GPIba + H2O
?
show the reaction diagram
-
-
-
-
?
growth factor alpha + H2O
?
show the reaction diagram
-
-
-
-
?
HB-EGF + H2O
?
show the reaction diagram
-
-
-
-
?
heparin-binding EGF-like growth factor + H2O
?
show the reaction diagram
-
-
-
-
?
ICAM-1 + H2O
?
show the reaction diagram
-
-
-
-
?
intercellular adhesion molecule-1 + H2O
?
show the reaction diagram
-
ADAM-17 mediates shedding of intercellular adhesion molecule-1. The shedding of intercellular adhesion molecule-1 reduces the adhesive capacity of the cells. the cleavage site in the intercellular adhesion molecule-1 is not sequence-specific, but appears to be nonselective
-
-
?
interleukin-6 receptor + H2O
soluble interleukin-6 receptor + ?
show the reaction diagram
-
-
-
-
?
L-selectin + H2O
?
show the reaction diagram
Notch 1 + H2O
?
show the reaction diagram
-
ADAM17 is required for Notch1 receptor proteolysis in NSCLC cells in vitro and in vivo
-
-
?
Notch1 + H2O
?
show the reaction diagram
-
-
-
-
?
p55 TNF-alpha RI + H2O
?
show the reaction diagram
-
-
-
-
?
p75 neurotrophin receptor + H2O
?
show the reaction diagram
p75 TNF-alpha RII + H2O
?
show the reaction diagram
-
-
-
-
?
preadipocyte factor 1 + H2O
?
show the reaction diagram
-
TACE is the major protease responsible for conversion of membrane-bound Pref-1 to the biologically active diffusible form
-
-
?
pro-EGF receptor + H2O
EGF receptor + ?
show the reaction diagram
-
-
-
-
?
pro-interleukin-6 receptor + H2O
interleukin-6 receptor + ?
show the reaction diagram
-
-
-
-
?
pro-L-selectin + H2O
L-selectin + ?
show the reaction diagram
-
-
-
-
?
pro-Notch 1 + H2O
Notch 1 + ?
show the reaction diagram
-
-
-
-
?
pro-TNF-alpha + H2O
soluble TNF-alpha + ?
show the reaction diagram
-
-
-
-
?
proTGF-alpha + H2O
soluble TGF-alpha
show the reaction diagram
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha + 9000 Da membrane-bound fragment of TNF-alpha
show the reaction diagram
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha + ?
show the reaction diagram
-
-
-
-
?
RA175/SynCAM1 + H2O
?
show the reaction diagram
-
neuronal RA175/SynCAM1 isoforms, members of the immunoglobulin family 4, are processed by TACE
-
-
?
receptor tyrosine kinase c-Kit + H2O
?
show the reaction diagram
-
ADAM-17 controls mast cell survival by regulating shedding and surface expression of c-Kit
-
-
?
TNF-alpha + H2O
?
show the reaction diagram
-
ranitidine enhances TNF-alpha production after lipopolysaccharide treatment through augmented p38 activation, and this seems to occur through TACE
-
-
?
TNF-alpha + H2O
soluble TNF-alpha
show the reaction diagram
vasorin + H2O
soluble vasorin + ?
show the reaction diagram
-
-
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Zinc
-
pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity
additional information
-
metalloprotease
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R,2R)-2-(3-phenoxylphenyl)-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
(1R,2R)-2-trans-carboisopropoxyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
(1R,2R)-2-trans-N-benzylaminocarbonyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
(1R,2R)-2-[3-(3,4-dichlorobenzyloxy)phenyl]-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
(1R,2R)-N-hydroxy-2-[(4-methylpiperazin-1-yl)carbonyl]-2-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxamide
-
-
(1R,2R)-N1-benzyl-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N1-cyclohexyl-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]-N1-phenylcyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-N1,N1-dimethyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-(3-fluoro-4-[[2-(1-methyl-1H-pyrazol-5-yl)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-(3-fluoro-4-[[2-(methylamino)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-morpholin-4-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxy-N1,N1-dimethylcyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-pyrrolidin-1-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[4-(benzyloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N1-(piperidin-4-ylmethyl)cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-N1-methyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1S,2R)-2-[[(3R)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
(1S,2R)-2-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
(1S,2R)-N-hydroxy-2-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
(1S,2R)-N-hydroxy-2-[[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
(1S,2R)-N-hydroxy-2-{4-[(2-imino-1,2-dihydroquinolin-4-yl)methoxy]benzyl}-2-(methoxycarbonyl)cyclopropanecarboximidic acid
-
-
(1S,2S)-2-((S)-cyano(4-((2-phenylquinolin-4-yl)methoxy)phenyl)methyl)-N-hydroxycyclopropanecarboxamide
-
-
(2R)-5-nitroguanyl-2-([(2R,3S)-2-(cyclohexylmethyl)-3-cyclopropyl-3-[formyl(hydroxy)amino]propanoyl]-amino)-N-(1,3-thiazol-2-yl)pentanamide
(2R)-N-hydroxy-2-(7-methoxy-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl)-3-methylbutanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(4-methylcyclohexyl)-methyl]hexanamide
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(5-methyl-2-thienyl)methyl]hexanamide
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutyl-4-methylpentanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutyl-4-methylpentanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-6,6,6-trifluoro-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-3-[formyl(hydroxy)amino]hexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-6,6,6-trifluoro-3-[formyl(hydroxy)amino]hexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-[(1S)-1-[formyl(hydroxy)amino]-2-phenylethyl]-4-methylpentanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[5-methyl-2-thienylmethyl]hexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]hexanamide
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
(2R,3S)-N-[(1S,2R)-4-nitroguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2R,3S)-N-{(1R)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl}-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
(2S)-2-amino-5-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-N-(1,3-thiazol-2-yl)pentanamide hydrochloride
(2S)-2-[(tert-butoxycarbonyl)amino]-5-({(Z)-(methyl-sulfanyl)[(methylsulfonyl)imino]methyl}amino)pentanoic acid
(2S,3R)-2-[(tert-butoxycarbonyl)amino]-5-{[imino(2-oxido-2-oxohydrazino)methyl]amino}-3-methylpentanoic acid (3R) Nalpha-boc-Ngamma-nitro-3-methyl L-arginine
(2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-5-({(Z)-(methylsulfanyl)[(methylsulfonyl)imino]methyl}-amino)pentanoic acid
(2S,3R)-5-methanesulfonylguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
(2S,3R)-5-nitroguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
(3R,4R)-4-([[4-(1,3-dihydrofuro[3,4-b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-([[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-([[4-(2,3-dihydrofuro[2,3-b]quinolin-4-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[([4-[(2,3-dimethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[([4-[(2-cyclopropylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[([4-[(2-ethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[([4-[(3-ethyl-2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-4-[[(4-[[2-(dimethylamino)quinolin-4-yl]methyl]phenyl)carbonyl]amino]-N-hydroxytetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[([4-[(2-morpholin-4-ylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[([4-[(3-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[[(4-[[2-(1-methylethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4R)-N-hydroxy-4-[[(4-[[2-(trifluoromethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-3-carboxamide
-
-
(3R,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
-
-
(3R,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
-
-
(3S)-1-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]pyrrolidine-3-thiol
-
-
(3S)-4-[[4-(but-2-ynylamino)phenyl]sulfonyl]-N-hydroxy-2,2-dimethylthio-morpholine-3-carboxamide
-
-
(3S,4R)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-3-carboxamide
-
-
(3S,4S)-1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-(2,2-dimethylpropyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-(butylsulfonyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-(furan-2-ylmethyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-acetyl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-but-2-yn-1-yl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-cyclobutyl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-1-tert-butyl-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
-
-
(3S,4S)-1-[2-(dimethylamino)ethyl]-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
-
-
(3S,4S)-3-[([4-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-3-[([4-[(2-ethyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-3-[([4-[(2-ethylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-3-[([4-[(2-tert-butylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(1-methylethyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(2-methylprop-2-en-1-yl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(2-methylpropanoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
-
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide
-
substance exhibits excellent oral bioavailability in pharmacokinetic studies
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-phenylpyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-prop-2-en-1-ylpyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
(3S,4S)-N-hydroxy-4-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]pyrrolidine-3-carboxamide
-
-
(4-bromobut-2-enyloxymethyl)benzene
-
-
(4-methoxyphenyl)acetic acid 4-benzyloxybut-2-enyl ester
-
-
(5R)-5-(2',4'-difluorobiphenyl-4-yl)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-(4'-chlorobiphenyl-4-yl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[2'-(1-methyl-1H-tetrazol-5-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(trifluoromethyl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(quinolin-6-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[3'-(2-methyl-1,3-thiazol-4-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(1H-pyrazol-3-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1,3-thiazol-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methyl-2H-indazol-6-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methylpyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(3-phenyl-1,2-oxazol-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(4-methyl-2,5-dioxoimidazolidin-4-yl)phenyl]imidazolidine-2,4-dione (non-preferred name)
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrazin-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrimidin-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(2-aminopyridin-4-yl)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(5-chloro-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R,6R)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.4]nonane-6-carboxamide
-
-
(5R,6S)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.4]nonane-6-carboxamide
-
-
(5R,7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-oxaspiro[4.4]nonane-7-carboxamide
-
-
(5S)-4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[(2S)-1-(2-[[(6S)-6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
-
90% inhibition at 0.04 mM
(5S)-5-(4-fluorophenyl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5S)-5-(4-hydroxybenzyl)-1-[(2S)-1-(2-[[(6S)-6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[2-(tricyclo[3.3.1.13,7]dec-1-yl)ethyl]piperazine-2,3-dione
-
95% inhibition at 0.04 mM
(5S,6R)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4-dioxo-1,3-diazaspiro[4.5]decane-6-carboxamide
-
-
(5S,6S)-N-hydroxy-5-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-2,3,5,6-tetrahydro-4aH-cyclopenta[b][1,4]dioxine-6-carboxamide
-
-
(5S,7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1-oxaspiro[4.4]nonane-7-carboxamide
-
-
(7S,8R)-N-hydroxy-8-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1,4-dioxaspiro[4.4]nonane-7-carboxamide
-
-
1,10-phenanthroline
1,25-dihydroxyvitamin D
-
1,25-dihydroxyvitamin D inhibition of TACE is a potential common mechanism underlying the efficacy of therapy with 1,25-dihydroxyvitamin D or its analogs to improve outcomes in chronic kidney disease. 1,25-dihydroxyvitamin D prevents/moderates not only the onset and progression of parathyroid TACE/TGFalpha-driven secondary hyperparathyroidism, but renal TACE/TGFalpha-driven fibrotic and inflammatory lesions to the renal parenchyma, and TACE/TNFalpha-driven systemic inflammation
1-(1,3-benzoxazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
1-(1H-benzimidazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
-
-
1-(2,2-dimethylpropyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-(butylsulfonyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-but-2-yn-1-yl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-ethylpropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-methyl-2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-methylethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
1-methylethyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
1-methylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-[(4-acetylpiperazin-1-yl)sulfonyl]-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
-
-
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
-
-
1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]-1,3,5-triazinane-2,4,6-trione
-
IC50: 0.0073 mM
13-[(4R)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]tridecanamide
-
-
2(R)-benzyloxymethyl-N-(2,2-dimethyl-1(S)-methyl-carbamoylpropyl)-3-(S)-(4-methoxyphenyl)succinamic acid
-
-
2,6-anhydro-3,4,5-trideoxy-1-(hydroxyamino)-3-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-D-threo-hexose
-
-
2-(3-benzyloxyphenyl)-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
2-(6-methyl-2-oxo-2H-chromen-3-ylmethyl)-pent-4-enoic acid hydroxyamide
-
-
2-(N-benzoxycarbonyl)aminoethyl-N-(4-hydroxyamino-4-oxo-2-(isopropylthio)butanoyl)-L-3-(2'-naphthyl)-L-alanyl amide
-
peptidomimetic inhibitor, 54.5% inhibition in in vitro lipopolysaccharide cytotoxicity tests, inhibitory activity in vivo by measuring the expression of mTNFalpha
2-(N-benzoxycarbonyl)aminoethyl-N-(4-hydroxyamino-4-oxo-2-(isopropylthio)butanoyl)-L-3-phenylalanyl-L-alanyl amide
-
peptidomimetic inhibitor, 27.3% inhibition in in vitro lipopolysaccharide cytotoxicity tests, molecular docking studies
2-(N-benzoxycarbonyl)aminoethyl-N-(4-hydroxyamino-4-oxo-2-(phenylthio)butanoyl)-L-3-phenylalanyl-L-alanyl amide
-
peptidomimetic inhibitor, 54.5% inhibition in in vitro lipopolysaccharide cytotoxicity tests
2-benzyl-N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
-
-
2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
2-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]acetamide
-
-
2-[(5R,6S)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]acetamide
-
-
2-[3-(2-methylquinolin-4-yl)methoxylphenyl]-2-trans-carboxamidocyclopropane hydroxyamic acid
-
-
2-[3-(2-methylquinolin-4-yl)methoxyphenyl]-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]acetamide
-
; IC50: above 0.1 mM
2-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]ethanethiol
-
-
2-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]ethanethiol
-
-
2-[[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl](methyl)amino]-N-hydroxyacetamide
-
-
3(R)-benzyloxymethyl-2-(S)-(4-methoxyphenyl)pent-4-enoic acid
-
-
3(R)-benzyloxymethyl-2-(S)-(4-methoxyphenyl)pent-4-enoic acid (2,2-dimethyl-1-(S)-methylcarbamoylpropyl)amide
-
-
3-(6-bromo-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
-
-
3-(6-chloro-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
-
-
3-(6-tert-butyl-2-oxo-2H-chromen-3-yl)-N-hydroxypropanamide
-
-
3-([[4-(1,3-dihydrofuro[3,4-b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-([[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-([[4-(2,3-dihydrofuro[2,3-b]quinolin-4-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2,3-dimethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2-cyclopropylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2-ethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(3-ethyl-2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoic acid
-
-
3-[[(4-[[2-(dimethylamino)quinolin-4-yl]methyl]phenyl)carbonyl]amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]cyclohexanethiol
-
-
3-[[4-(but-2-yn-1-ylamino)phenyl]sulfonyl]propane-1-thiol
-
-
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]cyclohexanethiol
-
-
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]cyclopentanethiol
-
-
3-[[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]propane-1-thiol
-
-
4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxamide
-
-
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
-
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
-
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
-
-
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-benzoyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-butyryl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(propane-2-sulfonyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-isobutyryl-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-pyridin-4-ylmethyl-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-1,4-dicarboxylic acid 1-diethylamide 4-hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
-
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
-
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
-
-
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-(dimethylsulfamoyl)-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dichlorothiophen-3-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dimethyl-1,3-thiazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)carbonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)methyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(5-chlorothiophen-2-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(morpholin-4-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(piperidin-1-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(pyrrolidin-1-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-2-ylpiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-4-ylpiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[(2-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
-
-
4-[(2-methylquinolin-4-yl)methoxy]-N-(1,3,5-trioxo-2,4-diazaspiro[5.5]undec-7-yl)benzamide
-
; IC50: 0.000138 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)benzamide
-
; IC50: above 0.1 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-2-oxa-7,9-diazaspiro[4.5]dec-4-yl)benzamide
-
; IC50: 0.000044 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-(6,8,10-trioxo-7,9-diazaspiro[4.5]dec-1-yl)benzamide
-
; IC50: 0.000024 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[1-(tetrahydro-2H-pyran-2-yl)piperidin-4-yl]hexahydropyrimidin-5-yl]methyl)benzamide
-
-
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]hexahydropyrimidin-5-yl]methyl)benzamide
-
IC50: 0.000031 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-([2,4,6-trioxo-5-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]hexahydropyrimidin-5-yl]methyl)benzamide
-
IC50: 0.00001 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-([5-[1-(methylsulfonyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)benzamide
-
IC50: 0.000029 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-([5-[4-(methylsulfonyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)benzamide
-
IC50: 0.000002 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[(2,4,6-trioxo-5-phenylhexahydropyrimidin-5-yl)methyl]benzamide
-
-
4-[(2-methylquinolin-4-yl)methoxy]-N-[(2,4,6-trioxo-5-piperidin-4-ylhexahydropyrimidin-5-yl)methyl]benzamide
-
; IC50: 0.000055 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)(pyridin-4-yl)methyl]benzamide
-
; IC50: 0.00236 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]benzamide
-
; IC50: 0.000026 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[2-(methylsulfonyl)-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl]benzamide
-
IC50: 0.000036 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[6,8,10-trioxo-2-(pyridin-3-ylcarbonyl)-2,7,9-triazaspiro[4.5]dec-4-yl]benzamide
-
IC50: 0.000029 mM
4-[(2-methylquinolin-4-yl)methoxy]-N-[[2,4,6-trioxo-5-(4-phenylpiperazin-1-yl)hexahydropyrimidin-5-yl]methyl]benzamide
-
-
4-[([4-[(1,1-dimethylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)methyl]-N-hydroxy-1-(isopropylsulfonyl)piperidine-4-carboxamide
-
-
4-[2-(hydroxyamino)-2-oxoethyl]-N,N-dimethyl-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-1-carboxamide
-
-
4-[4-(4-hydroxy-but-2-ynylamino)-benzenesulfonylmethyl]-4-hydroxycarbamoyl-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
5-(4-acetylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00062 mM
5-(4-benzylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000195 mM
5-(4-hexylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000081 mM
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
-
-
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamanylpropyl]piperazine-2,3-dione
-
-
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
-
-
5-(4-methylpiperazin-1-yl)-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000091 mM
5-methyl-5-(2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]ethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
; IC50: 0.049 mM
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-3-oxopropyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
; IC50: 0.0008 mM
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.011 mM
5-methyl-5-(3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]propyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
; IC50: above 0.1 mM
5-methyl-5-[(2E)-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]prop-2-en-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
; IC50: 0.0022 mM
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenoxy]pyrimidine-2,4,6(1H,3H,5H)-trione
-
; IC50: 0.0013 mM
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]dihydropyrimidine-2,4(1H,3H)-dione
-
IC50: 0.0037 mM
5-methyl-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-phenylimidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(2-phenoxyphenyl)imidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(3-phenoxyphenyl)imidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-oxopyrrolidin-1-yl)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(morpholin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yloxy)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrrolidin-1-ylcarbonyl)phenyl]imidazolidine-2,4-dione
-
-
5-[4-(1-methylethyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000096 mM
5-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00054 mM
5-[4-(2,2-dimethylpropyl)piperazin-1-yl]-5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00016 mM
5-[4-(cyclopentyloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
5-[4-(isoquinolin-7-yloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-(pyridin-3-ylcarbonyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000535 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-piperazin-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.0011 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-piperidin-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000855 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(2-phenylethyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000084 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(3-phenylpropyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.00011 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(4-nitrophenyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.0028 mM
5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-5-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione
-
IC50: 0.000275 mM
7-(1-methyl-2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
7-(2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
7-(3-methyl-2,5-dioxoimidazolidin-4-yl)-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
7-[(4R)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
7-[(4S)-2,5-dioxoimidazolidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]heptanamide
-
-
APMA
-
inhibits TACE completely
BB 1101
-
-
BB 1433
-
-
BB 16
-
-
BB 2516
-
-
BB2275
-
-
-
BB2284
-
-
-
BB3103
benzyl (1S,2R)-4-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
BMS-561392
CGS 27023
-
-
CT 572
-
-
-
cyclohexyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclohexylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclopentyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclopropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
dithiothreitol
-
-
doxorubicin
-
-
DPH-067517
-
-
EGTA
-
1 mM, treatment of cells dramatically inhibits shedding of shedding of FcalphaR, i.e. Fc receptor for immunoglobulin A
ethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[3-bromo-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[3-chloro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[3-fluoro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-phenoxybenzyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(2-methylpropyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(trifluoromethyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylpyridin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
gelastatin hydroxamate
-
-
GI 129471
-
-
GM 6001
-
-
GM6001
GW 3333
GW1988
-
-
-
GW280264X
GW9471
Hydroxamate
IC-3
-
protects TACE from degradation by inhibiting either TACE itself or another metalloprotease
Immunex compound 3
-
-
JMV 390
-
-
KB-R7785
-
-
L-NG-(2-pyridylsulfonyl)arginine2-aminothiazole amide hydochloride
L-NG-nitroarginine 2-aminothiazole amide dihydrochloride
macrocyclic hydroxamic acid
methyl (1R,2R)-1-[3-(2-[3-[(1Z)-buta-1,3-dien-1-yl]phenyl]ethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(benzyloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(but-2-yn-1-yloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(cyclohexylmethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-[(4-chlorobenzyl)oxy]phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-methoxyphenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[3-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[4-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-naphthalen-2-ylethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-phenylethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(4-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-ylmethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-yloxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(3-methoxybenzyl)oxy]phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(benzyloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(cyclohexylmethoxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-[(2-chlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-[(3,4-dichlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-1-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-2-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
methyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
methyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
methyl (5R)-5-{7-[(3,5-diethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate
-
-
methyl (5R)-5-{7-[(3,5-dimethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate
-
human whole blood assay: 31% inhibition
methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazin-1-ylcarbonyl)-5-azaspiro[2.5]octane-5-carboxylate
-
i.e. INCB7839, selective inhibitor of endopeptidases ADAM-10 and ADAM-17
methyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
methyl 4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxylate
-
-
methyl 4-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,5-dioxoimidazolidine-4-carboxylate
-
IC50: 0.0047 mM
MMP-1
-
-
-
MMP-2
-
-
-
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
N-(2-acetyl-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000055 mM
N-(8-acetyl-1,3,5-trioxo-2,4,8-triazaspiro[5.5]undec-11-yl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-([5-[1-(1-methylethyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
; IC50: 0.000052 mM
N-([5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000013 mM
N-([5-[4-(1-methylethyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
; IC50: 0.000007 mM
N-([5-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000029 mM
N-([5-[4-(5-amino-8-carbamimidamido-4-oxooctyl)piperazin-1-yl]-2,4,6-trioxohexahydropyrimidin-5-yl]methyl)-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-2(R)-(6-methoxy-1,1-dioxo-3,4-dihydro-1H-1-benzo[1,2,4]thiadiazin-2-yl)propionamide
-
-
N-hydroxy-2(R)-[2,3,4,5-tetrahydrobenzo[1,2,5-f]-thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(2,6-methylpyridyl-4-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propanamide
-
human whole blood assay: 37% inhibition
N-hydroxy-2(R)-[7-(2-trifluromethylphenyl)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide
-
-
N-hydroxy-2(R)-[7-(3,5-dichlorobenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 12% inhibition
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
human whole blood assay: 17% inhibition
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide
-
human whole blood assay: 0% inhibition
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 26% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine 1,1-dioxide]-6-N-(methanesulfonyl)hexylamide
-
-
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
human whole blood assay: 11% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide
-
human whole blood assay: 0% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide
-
human whole blood assay: 16% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-aminohexylamidetrifluoroacetic acid salt
-
human whole blood assay: 3% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-N-[(1,1-dimethylethoxy)carbonyl]hexylamide
-
human whole blood assay: 3% inhibition
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(3,5-dimethylbenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 2% inhibition
N-hydroxy-2(R)-[7-(3-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(4,5-dimethylthiazolyl-2-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide
-
human whole blood assay: 0% inhibition
N-hydroxy-2(R)-[7-(4-methoxyphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(4-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(4-phenylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-(4-trifluoromethylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 58% inhibition
N-hydroxy-2(R)-[7-(N-3,5-dimethylbenzoylamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propylamide
-
-
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide
-
human whole blood assay: 39% inhibition
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 30% inhibition
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide
-
human whole blood assay: 20% inhibition
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
human whole blood assay: 21% inhibition
N-hydroxy-2(R)-[7-methoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-N-(3,5-dimethoxymethyleneamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide
-
human whole blood assay: 3% inhibition
N-hydroxy-2(R)-[7-phenoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide
-
-
N-hydroxy-2(R)-[7-phenyl-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide
-
-
N-hydroxy-2-((6-methoxy-2H-chromen-3-yl)methyl)propanamide
-
-
N-hydroxy-2-(2-oxo-2H-chromen-3-yl)acetamide
-
-
N-hydroxy-2-methyl-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
-
-
N-hydroxy-2-[2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide
-
-
N-hydroxy-2-[7-methoxy-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide
-
-
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-[([4-[(2-morpholin-4-ylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-3-[([4-[(3-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-3-[[(4-[[2-(trifluoromethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-(methylsulfonyl)piperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-propylpiperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]tetrahydro-2H-pyran-4-carboxamide
-
-
N-[(1R,2S)-2-(hydroxycarbamoyl)-4-oxocyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1R,2S)-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1R,2S)-4,4-difluoro-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1R,2S)-4-aziridin-1-yl-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1R,2S)-4-hydroxy-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(1S,2R)-2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(4-methyl-2,5-dioxoimidazolidin-4-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(4S,5S,7R)-2-[7-(1-benzylpiperidin-4-yl)]methylcarbamoyl-5-hydroxy-2-methyloct-4-yl]-N'-[(R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]isophthalamide
-
-
N-[(5-benzyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000018 mM
N-[(5-ethyl-2,4,6-trioxohexahydropyrimidin-5-yl)methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
; IC50: 0.000016 mM
N-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(5R,6R)-2,4-dioxo-1,3-diazaspiro[4.5]dec-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(5R,6S)-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(5R,9R)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[(5R,9R)-7-(2-methylpropanoyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(1,1-dimethylprop-2-yn-1-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2,2-dimethylpropanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2,2-dimethylpropyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2,5-dioxoimidazolidin-4-yl)ethyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2-fluoroethyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(3,3-dimethylbutanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(4,5-dihydro-1,3-thiazol-2-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-acetyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-ethyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-tert-butyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-[2-(ethylsulfonyl)ethyl]-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-[2-(hydroxyamino)-2-oxoethyl]cyclohexyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-[2-(hydroxyamino)-2-oxoethyl]cyclohexyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[2-(2,2-dimethylpropanoyl)-6,8,10-trioxo-2,7,9-triazaspiro[4.5]dec-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000111 mM
N-[2-(hydroxycarbamoyl)cyclobutyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)acetamide
-
IC50: 0.012 mM
N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-3-(5-methyl-2,4,6-trioxohexahydropyrimidin-5-yl)propanamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(2-methylpropanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(3-methylbutanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(methylsulfonyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-methylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-phenylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propanoylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-[2-(methylsulfonyl)ethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydrofuran-3-yl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[DL-[2-(hydroxyamino-carbonyl)methyl]-4-methylpentanoyl]-L-3-(tert-butyl)glycyl-L-alanine,2-aminoethylamide
-
-
N-[[(4R)-2,5-dioxoimidazolidin-4-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[[1-(hydroxycarbamoyl)cyclohexyl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[[5-(1-methylethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
; IC50: 0.000019 mM
N-[[5-(1-methylpiperidin-4-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
; IC50: 0.000057 mM
N-[[5-(4-acetylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
; IC50: 0.000005 mM
N-[[5-(4-benzylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000014 mM
N-[[5-(4-ethynylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
IC50: 0.000062 mM
N-[[5-(4-methylpiperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
; IC50: 0.000058 mM
N1-benzyloxy-2(R)-benzyloxymethyl-N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-3(S)-(4-methoxyphenyl)-succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(R)-(isobutyl)succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-(4-methoxyphenyl)succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-p-tolylsuccinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-phenylsuccinamide
-
-
NaCl
-
dramatic inhibitory effect on the activity of TACE
peptide hydroxamate
-
-
-
peptidomimetic hydroxamate
-
-
-
PKF241-466
-
maximum inhibition at 10 mg/kg
PKF242-484
pyridin-4-ylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
Ro 31-9790
-
-
Ro 32-7315
-
-
Ro32-7315
-
inhibitor specific for ADAM17, blocks shedding of CD30 antigen from cell membrane and a simultaneous release of soluble CD30
SC 903
-
-
-
SE 205
-
-
succinate
-
-
succinyl hydroxamate
-
-
sulfonamide hydroxamate
-
-
sunitinib
-
-
TACE-pro domain
TAPI-1
TAPI-2
tert-butyl (1S,2R)-4-{[imino(2-oxido-2-oxohydrazino)-methyl]amino}-2-methyl-1-[1,3-thiazol-2-ylaminocarbonyl]butylcarbamate
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-4-pentenoate
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-amino-3-methylpentanoate
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-azido-3-methylpentanoate
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-hydroxy-3-methylpentanoate
tert-butyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
tert-butyl (3S,4S)-3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
tert-butyl (5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)carbamate
-
; IC50: 0.000013 mM
tert-butyl (5R,9R)-9-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate
-
-
tert-butyl 11-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-1,3,5-trioxo-2,4,8-triazaspiro[5.5]undecane-8-carboxylate
-
-
tert-butyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
tert-butyl 3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoate
-
-
tert-butyl 4-(5-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2,4,6-trioxohexahydropyrimidin-5-yl)piperazine-1-carboxylate
-
IC50: 0.00016 mM
tert-butyl 4-(5-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-2,4,6-trioxohexahydropyrimidin-5-yl)piperidine-1-carboxylate
-
; IC50: 0.000047 mM
tert-butyl 4-(hydroxycarbamoyl)-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-1-carboxylate
-
-
tert-butyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
tert-butyl 4-([[4-(but-2-ynylamino)phenyl]sulfonyl]methyl)-4-[(hydroxyamino)-carbonyl]piperidine-1-carboxylate
-
-
tert-butyl 4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]-6,8,10-trioxo-2,7,9-triazaspiro[4.5]decane-2-carboxylate
-
IC50: 0.000128 mM
tert-butyl 4-[([4-[but-2-ynyl(methyl)amino]phenyl]sulfonyl)methyl]-4-[(hydroxyamino)carbonyl]piperidine-1-carboxylate
-
-
tert-butyl(1S)-4-({(Z)-(methylsulfanyl)[(methylsulfonyl)-imino]methyl}amino)-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
TIMP-3
tissue inhibitor of metalloproteinase-3
-
-
-
tissue inhibitor of metalloproteinases-3
-
natural inhibitor of ADAM17
-
TMI-1
-
-
TMI-2
-
complete inhibition at 50 nM
TNF-alpha proteinase inhibitor
-
0.00005 mM
-
tumor necrosis factor-alpha protease inhibitor
-
-
-
tumor necrosis factor-alpha-converting enzyme pro domain
-
inhibition of the tumor necrosis factor-alpha-converting enzyme by its isolated pro domain, IC50: 70 nM
-
[((3R,4S)-4-{[(benzyloxy)carbonyl]}-4-carboxy-3-methylbutyl)amino](imino)methanaminium nitrate (3R) 3-methyl L-arginine nitric acid salt
[N-hydroxy-1-(isopropylsulfonyl)-4-[(4-[(1-methylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)-methyl]piperidine-4-carboxamide
-
-
additional information